{
  "trial_id": "NCT01595737",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "LVEF \u2264 35%",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Indication for elective surgery for coronary revascularisation, with or without mitral valve repair.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Freely choose to participate in trial and sign an informed consent",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "The patient does not accept the protocol.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Allergy (hypersensitivity) to levosimendan, any of its components or to riboflavin.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Severe hypotension or severe tachycardia prior to entering study.",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Significant mechanical obstruction affecting ventricular filling and/or emptying.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has Marfan's syndrome and severe mitral valve prolapse with regurgitation, but remains symptomatic and is prepared to undergo surgery. EF of 65% on TTE.",
  "_meta": {
    "topic_id": "12",
    "trial_id": "NCT01595737",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}